Frankenfield Christopher James
- SEC CIK
- 0001988344
In the past year, 1 open-market sale filing worth $4.50K and no purchases.
Current role at each company
- XLO Xilio Therapeutics, Inc.Chief Financial Officeras of Jan 5, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $4.50K
- 1 filing
- Net
- −$4.50K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Frankenfield Christopher James as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Frankenfield Christopher JamesChief Financial Officer | SSale | −7.03K | $0.64 | −$4.50K | −22.1%24.8K after | 10b5-1 |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Frankenfield Christopher JamesChief Financial Officer | SSale | −6.95K | $0.98 | −$6.81K | −35.9%12.4K after | 10b5-1 |